The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

Publication date: July 2018
Source:Digestive and Liver Disease, Volume 50, Issue 7
Author(s): Fabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, Mariangela Scolaro, Antonio Magnano, Dario Pluchino, Maria Cappello, Gaetano Cristian Morreale, Sebastiano Siringo, Antonino Carlo Privitera, Concetta Ferracane, Nunzio Belluardo, Nadia Alberghina, Marco Ventimiglia, Giulia Rizzuto, Sara Renna, Mario Cottone, Ambrogio Orlando
BackgroundThe effectiveness of vedolizumab in real-world practice is under evaluation, while its role in inflammatory bowel disease-associated spondyloarthritis is still unclear.AimsTo report real-world data about the effectiveness of vedolizumab on intestinal and articular symptoms after 10 and 22 weeks of treatment.MethodsWeb-based data from the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) were extracted to perform a prospective multicentre observational study.Results163 patients (84 with Crohn’s disease and 79 with ulcerative colitis) were included. At week 10, a steroid-free remission was achieved in 71 patients (43.6%), while at week 22 a steroid-free remission was obtained in 40.8% of patients. A response on articular symptoms was reported after 10 weeks of treatment in 17 out of 43 (39.5%) patients with active spondyloarthritis at baseline, and in 10 out of 22 (45.4%) patients at week 22. The only factor associated with articular response was the coexistence of clinical benefit on intestinal symptoms (at week 10: OR 8.471, p = 0.05; at week 22: OR 5.600, p = 0.08).ConclusionsVedolizumab showed good effectiveness after 10 and 22 weeks of treatment. A subset of patients reported improvement also on articular symptoms, probably as a consequence of the concomitant control of gut inflammation.